A new clinical trial involving mazdutide was listed on ClinicalTrials.gov on July 21, 2026. The study, titled "Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)," is registered under identifier NCT07718126.
The trial is designated Phase 2/3 and its current status is listed as not yet recruiting. According to the registration, the study focuses on obese individuals with MASLD who are being evaluated as living liver donors, with mazdutide administered as part of a pre-hepatectomy rehabilitation approach.
No results, efficacy data, or safety outcomes have been posted for this trial at this time. The listing reflects only the trial's design and planned scope as registered.
Mazdutide remains an unapproved compound under research and has not received regulatory approval for the use described in this trial. As the study has not yet begun recruiting participants, further details about enrollment criteria, timelines, and outcomes are expected to be released as the trial progresses.
Readers interested in learning more about mazdutide, including its background and other research activity, can refer to the compound overview for additional context.